bluuebunny/crossref_metadata_2025_split huggingface dataset:
Vincristine and prednisone vs vincristine, l‐asparaginase, and prednisone for second remission induction of acute lymphocytic leukemia in children
Authors: Herson Jay , Starling Kenneth A. , Dyment Paul G. , Humphrey G. Bennett , Pullen Jeanette , Vats Tribhawan 
Published: February 2007

AbstractSecond remission induction rates for vincristine and prednisone alone (VP) and vincristine, L‐asparaginase, and prednisone (VLP) are compared for children with acute lymphocytic leukemia. No evidence of a significant difference between the second induction complete remission rate for VP (78.6%) and VLP (73.7%) was found. Duration of first remission and prognostic group at initial diagnosis (defined on the basis of age and white blood count at initial diagnosis) are shown to be significant prognostic factors for second remission induction; and three second remission induction risk groups are defined on the basis of these two factors. Periodic reinforcement with prednisone in first remission does not appear to lower second induction complete response (CR) rates for VP. There was no evidence of a significant difference in the frequency of occurrence of severe toxicity between the VP and VLP regimens.
Leukemic phase of malignant histiocytosis (arguments in favour of the histiomonocytic origin of the abnormal cells)
Authors: Harousseau J. L. , Degos L. , Daniel M. T. , Flandrin G. 
Published: February 2007

AbstractA 15‐year‐old female was treated for malignant histiocytosis. The occurrence of a leukemic phase (178,000 blasts/cu mm) during the follow up provided the opportunity of studying a large number of malignant cells by cytochemical, electron microscopic, and cell membrane markers techniques. Acid phosphatase reaction was strongly positive and totally inhibited by tartaric acid. Nonspecific esterase reaction was moderately positive with inhibition by sodium fluorid. Electron microscopy revealed the presence of surface membrane pseudopods and the phagocytic activity of the cells. The leukemic cells had a receptor for the Fc fragment of IgG. These findings support the histiomonocytic origin of the abnormal cells in malignant histiocytosis.
Combination chemotherapy for bone marrow relapse in childhood lymphoblastic leukaemia (all)
Authors: Chessells Judith M. , Cornbleet Michael 
Published: February 2007

AbstractThirty‐four children with acute lymphoblastic leukaemia (ALL) in relapse or resistant to initial induction received combination chemotherapy with prednisolone, vincristine, 1‐asparaginase, and daunorubicin. L‐asparaginase was given subcutaneously on alternate days for four weeks and was well tolerated. A complete remission was achieved in 96% of children in relapse and in five out of six children resistant to induction. Remission was achieved without hospitalisation in over 60% of patients.The median duration of subsequent remission was only 13 weeks, but six out of eight children receiving a second course of the drug combination achieved a further remission. We conclude that prolonged 1‐asparaginase therapy in combination with an anthracycline might well be used in initial or consolidation therapy for childhood ALL.
Ewing sarcoma: Treatment with high dose radiation and adjuvant chemotherapy
Authors: Graham‐Pole John 
Published: February 2007

AbstractTwenty‐one patients with pathologically proven Ewing sarcoma without overt metastases at diagnosis were treated with a protocol were treated with a protocol designed by the Royal Marsden/St. Bartholomew's Hospitals Children's Solid Tumour Group (CSTG). They received megavoltage radiotherapy to the involved bone and adjuvant chemotherapy with a combination of four cytotoxic drugs. Seven patients have so far relapsed, four at the original site and three in other bones. The other 14 are clinically free of disease a median of 36 months from diagnosis. Comparison with a historical control group of 19 patients treated with surgery or radiotherapy, but without initial chemotherapy, shows a significant improvement in survival for the study group (P = 0.03). Seventeen of the controls have died.The treatment regime was moderately toxic, but there were no treatmentrelated deaths. These results confirm that an improved survival time and hopefully cure rate can be expected from treating Ewing tumour with high doses of megavoltage radiation and combination chemotherapy. Future goals must be the better control of large primary lesions and the eradication of micrometastases in other bones. The place of surgery should be re‐evaluated in the treatment of the primary tumour, and better adjuvant chemotherapy regimes are needed.
Chromosome 1 abnormalities in relapse and terminal stages in childhood leukemia
Authors: Morse Helvise , Hays Taru , Rose Barbara , Robinson Arthur 
Published: February 2007

AbstractSeven of 114 children with leukemia were shown to have abnormalities of chromosome 1. These included trisomy of parts of chromosome 1 as well as translocations of chromosome 1 to other chromosomes. The abnormalities were found during a relapse or terminal stage, after which the patient was refractory to therapy in all cases.
Childhood leukemia and lymphoma: Correlation of clinical features with immunological and morphological studies
Authors: Quinn John J. , Taylor Clive R. , Swanson Virginia , Williams Arthur H. , Schneider Barbara K. , Higgins Gussie R. , Tindle Barbara H. , Powars Darleen , Lincoln Thomas , Chandor Stebbins B. , Pattenagle Paul , Siegel Stuart E. , Lukes Robert J. 
Published: February 2007

AbstractMalignant cells from 49 children with lymphoid neoplasms other than Hodgkin disease were evaluated by surface marker and morphologic studies. We classified the patients into three groups: 36 patients (74%) with acute lymphocytic leukemia; 7 (14%) classified as convoluted lymphocytic lymphoma/leukemia; and 6 (12%) with small noncleaved follicular center cell lymphoma/leukemia; and 6 (12%) with small noncleaved follicular center cell lymphoma/leukemia. Diffuse marrow involvement was present at diagnosis in some patients in the latter two groups, but their clinical course was not characteristic of the patients with acute lymphocytic leukemia. Male predominance, poor prognosis, and high incidence of central nervous system disease characterized patients in the convoluted lymphocytic and follicular center cell lymphoma/leukemia groups. Clinical presentation in these two groups differed. Proliferations of convoluted lymphocytes were associated with mediastinal masses and proliferations of follicular center cells with intraabdominal tumors. The high incidence of CNS disease in children with neoplasms of convoluted lymphocytes and follicular center cells suggests that these processes have a predilection for the CNS and that patients with them may benefit from CNS prophylaxis.
Orbital rhabdomyosarcoma in a neonate
Authors: Harlow Paul J. , Kaufman Francine R. , Siegel Stuart E. , Quevedo Eduarita 
Published: February 2007

AbstractA newborn with a pleomorphic rhabdomyosarcoma of the eyelid was treated by chemotherapy, surgery, and radiation therapy and experienced a good response. The nine previous cases in the literature are reviewed and this patient's therapy discussed.
Management of localized thoracic neuroblastoma
Authors: Castleberry R. P. , Crist William M. , Cain Walter S. , Holbrook Tate , Malluh Ahmad , Salter Merle M. 
Published: February 2007

AbstractThirteen children with localized (Evans stage I or II) thoracic primary neuroblastoma were divided into two groups according to the type of therapy administered, in order to compare the therapeutic efficacy and morbidity of excisional surgery followed by either irradiation alone or irradiation plus chemotherapy (group A) with similar surgery alone (group B). Group A consisted of 6 children (mean age 1 year, 2 months). Complete surgical excision was accomplished in 2 patients, while 4 had microscopic residual. All 6 patients are free of disease at 23–76 months (mean 47 months), including 2 who had recurrent tumor and received additional therapy. Two have developed congestive heart failure and one severe scoliosis secondary to irradiation.Of the 7 children in group B (mean age 2 years, 2 months), 3 had microscopic residual tumor and 2 had adjacent lymph node involvement. After 12–47 months (mean 23 months), no recurrence or surgery‐related morbidity has been observed. From these limited data it appears that surgery alone may provide adequate therapy for localized thoracic neuroblastoma and obviate the morbidity associated with multimodal therapy.
Tumor lysis pancreatitis
Authors: Spiegel Robert J. , Magrath Ian T. 
Published: February 2007

AbstractRapid tumor lysis may produce acute complications including systemic metabolic disturbances and hemorrhage in sites involved by tumor. We have observed two cases of acute pancreatitis induced by the lysis of lymphoma that involved the pancreas. This previously unreported cause of pancreatitis must be added to the list of potential complications associated with effective cancer chemotherapy.
An unusual case of T‐cell lymphoproliferative disorder
Authors: Spanos George , Kanter Robert J. , Rosner Fred , Grünwald Hans W. 
Published: February 2007

AbstractA 54‐year‐old woman with epigastric pain had leukocytosis of 73,000/μ1 consisting mainly of atypical lymphoid cells with convoluted and cleaved nuclei resembling Sézary cells; the bone marrow aspirate was nondiagnostic. Skin biopsy was unremarkable. The patient also had hypercalcemia and hemolysis with a positive direct Coombs' test, both of short duration.The arterial oxygen tension was decreased, but there was no demonstrable lung pathology. The patient subsequently developed rapidly enlarging lymphadenopathy. Lymph node biopsy was interpreted as “undifferentiated pleomorphic lymphoma.” Immunologic functional studies revealed that the majority of the peripheral blood atypical lymphoid cells from involved lymph nodes formed rosettes with sheep erythrocytes.The lymphadenopathy regressed transiently after the administration of chemotherapy and the white blood cell count decreased from a maximum of 385,000/μ1 to 3,500/μ1, at which point the arterial oxygen tension returned to normal. The unusual features of this patient are discussed in light of the known characteristics of the various types of T‐cell lymphoproliferative disorders.
Results of multimodal therapy for children with neurogenic sarcoma
Authors: Raney R. Beverly , Littman Philip , Jarrett Patricia , Waldman Maria T. G. , Chatten Jane 
Published: February 2007

AbstractThe courses of 18 children with neurogenic sarcoma (NS) treated at the Children's Hospital of Philadelphia between 1958 and 1979 were reviewed. Their median age was 11 years (range, 0.3–16 years); 12 were female and six male. Eleven children had stigmata of neurofibromatosis (NF). One patient had two separate tumors simultaneously. Nine of the tumors were primary in an extremity; six were intraabdominal, two craniofacial, and two truncal. Eleven of the 18 children had grossly complete surgical removal of the primary tumor, whereas seven had gross residual disease after surgery; none had distant metastases detected at diagnosis. The patients were divided into two groups according to whether treatment was primarily surgical (group A) or multimodal (group B). Treatment for group B patients included surgery, local radiotherapy, and multiple‐agent chemotherapy. Two of 12 patients (17%) treated primarily with surgery are surviving four and 14 years later with no evidence of recurrent disease (NED); both had complete removal of the primary NS. Two additional group A patients relapsed but were retrieved with radiotherapy and multiple‐agent chemotherapy. The other eight patients in group A died of tumor at a median of 14 months from diagnosis. In contrast, five of the six group B patients (83%) treated with adequate multimodal therapy (at least 4,000 rads local radiation plus vincristine, actinomycin D, and cyclophosphamide ± Adriamycin) are relapse‐free and surviving at a median of 27+ months from diagnosis. Nine of the 18 patients are free of disease, four with and five without NF. The results suggest that multimodal therapy similar to that for rhabdomyosarcoma should be used for children with neurogenic sarcoma.
Unusual cytogenetics in a case of acute lymphoblastic leukemia
Authors: Morse Helvise G. , Hays Taru , Odom Lorrie F. 
Published: February 2007

AbstractThe cytogenetics in the study of a patient with acute lymphoblastic leukemia are presented. Initially, a large proportion of both unstimulated and phytohemagglutinin (PHA)‐stimulated blood mitoses showed an abnormal karyo‐type with a 7;12 translocation and a trisomy 19. At the time of relapse, a PHA‐stimulated culture showed the clonal abnormality as well as dicentric chromosomes in normal cells, the latter possibly resulting from treatment.
Micrococcus luteus pneumonia: A case report and review of the literature
Authors: Souhami Luis , Feld Ronald , Tuffnell Peter G. , Feller Tamison 
Published: February 2007

AbstractThe clinical course of a 69‐year‐old male with acute myelogenous leukemia is described who, while extremely leukopenic (<100 neutrophils/μ1) from chemotherapy, developed a cavitating pneumonia due to a gram‐positive coccus, Micrococcus luteus. Aggressive antibiotic management and attainment of complete remission of his leukemia resulted in a successful outcome. A review of the literature regarding the pathogenicitiy of this organism and, in particular, its occurrence as a cause of pneumonia is presented.
Acute leukemia in pregnancy: Transient neonatal myelosuppression after combination chemotherapy in the mother
Authors: Okun David B. , Groncy Paula K. , Sieger Lance , Tanaka Kouichi R. 
Published: February 2007

AbstractAn 18‐year‐old primagravida received combination chemotherapy with vincristine, prednisone, L‐asparaginase, cyclophosphamide, daunomycin, 6‐mercaptopurine and central nervous system (CNS) prophylaxis with intrathecal methotrexate and whole‐brain irradiation for acute lymphoblastic leukemia (ALL) beginning in the 12th week of pregnancy. Therapy resulted in sustained complete remission of the leukemia and delivery of a normally developed female infant whose immediate neonatal course was complicated by transient severe bone marrow hypoplasia. Our experience confirms the reports of others that intensive chemotherapy can be administered in the last two trimsters of pregnancy without serious teratogenic complications. However, we conclude that such therapy may cause significant myelosuppression in the newborn.
Prostate cancer mimicking malignant lymphoma
Authors: Oster Martin W. , Wolff Marianne , Starrett Sheree 
Published: February 2007

AbstractWe report three patients evaluated on a medical service for lymphoma‐like signs and symptoms. Although none had prostate or bone symptomatology, all three were found to have metastatic prostate cancer. These cases emphasize the propensity of prostate cancer to metastasize to lymph nodes as well as bones. Diagnostic and therapeutic implications are discussed.
Hepatotoxicity in the treatment of acute lymphoblastic leukaemia
Authors: Topley J. M. , Benson J. , Squier M. V. , Chessells J. M. 
Published: February 2007

AbstractSerial liver function tests and percutaneous liver biopsies were performed on 21 children receiving treatment for acute lymphoblastic leukaemia (ALL). The patients received continuing chemotherapy either with daily 6‐mercaptopurine and weekly methotrexate or with five‐day pulses of these drugs every three weeks.Liver function tests were transiently abnormal in the majority of children, but the abnormalities bore no relationship to the histology of the liver biopsy. Mild inflammatory and fatty changes were commonly seen, and early portal fibrosis was found in three out of 16 patients biopsied at between 108–130 weeks on treatment. There was no correlation between treatment regime and results of biopsy. Three patients showed possible progression of abnormalities on repeat biopsy.The risk of development of portal fibrosis appears low after 2–3 years of continuing chemotherapy, but examination of liver histology may be indicated if more prolonged therapy is contemplated.
Serum phosphodiesterase I activity in breast cancer patients
Authors: Bender John W. 
Published: February 2007

AbstractSerum phosphodiesterase I (PDE I) activity was determined in 13 control and 51 breast‐cancer patients with various stages of disease. Patients with both localized and metastatic breast cancer had significantly elevated serum PDE I activity. The highest activity was seen in patients with liver metastases. A decline in serum PDE I activity was seen after surgical resection of all known disease.
Changes of CSF‐protein pattern in children with acute lymphoblastic leukemia during prophylactic cns therapy (Berlin protocol)
Authors: Siemes H. , Rating D. , Siegert M. , Hanefeld F. , Müller St. , Gadner H. , Riehm H. 
Published: February 2007

AbstractThe cerebral spinal fluid (CSF)‐protein profiles of ten children with previously untreated acute lymphoblastic leukemia (ALL) were investigated by agarose gel electrophoresis. The profiles were determined at diagnosis and during the fifth to eighth week of treatment when preventive therapy for central nervous system (CNS) leukemia (skull) irradiation, intrathecal methotrexate (ithMTX) was administered. The profiles were compared with those obtained from a control group of 67 children and those from 42 patients with acute aseptic meningitis. The data from the latter group demonstrated the CSF‐protein pattern of partial blood‐CSF barrier (B‐CSF‐B) breakdown. The children with ALL showed no or only minor signs of a B‐CSF‐B impairment at diagnosis and after four weeks of systemic treatment. However, CSF changes indicative of a lesion of the B‐CSF‐B increased in all children continuously during CNS prophylaxis. The protein profile at the end of combined chemotherapy and radiotherapy was very similar to that in patients with acute aseptic meningitis. These observations point to neurotoxic side effects on the CNS barrier system with the combination of cranial radiation and ithMTX. A striking finding was restricted heterogeneity of γ‐globulin, observed in the CSF of nine out of the ten children with ALL before or during treatment. The significance of this abnormality is unknown.
Successful chemotherapy for childhood metastatic embryonal cell carcinoma of the testicle: A preliminary report
Authors: Holbrook C. Tate , Crist William M. , Cain Walter , Bueschen Anton 
Published: February 2007

AbstractA child with widespread metastases successfully treated with chemotherapy alone is described. One course of combination chemotherapy using cis‐platinum, vinblastine, and bleomycin produced disappearance of multiple pulmonary metastatic lesions. Four courses of therapy produced shrinkage and tumor sterilization of an abdominal mass. Twenty‐six months after initiation of chemotherapy the patient is well, off of all therapy for fourteen months, and free of disease or drug related complication with normal creatinine clearance and alpha‐fetoprotein determinations.The published adult experience demonstrates that this therapy is extremely effective for the treatment of metastatic embryonal cell carcinoma of the testis in young adults, and our case report extends this favorable experience into childhood. Toxicity is substantial, but justifiable considering the poor outlook associated with widespread metastatic disease. Collectively, the reviewed data suggest that further trials of this type of therapy are indicated in children.
Delayed allergic reactions following intramuscular L‐asparaginase
Authors: Spiegel Robert J. , Echelberger Candyce K. , Poplack David G. 
Published: February 2007

AbstractL‐asparaginase, a highly effective anti‐leukemic enzyme preparation, is now frequently being adminstered intramuscularly in order to decrease the incidence of severe sensitivity reactions. Although the occurrence of immediate hypersensitivity reactions and anaphylaxis has been diminished through this technique, we report three patients who developed delayed allergic reactions occurring hours after drug administration. This suggests that patients receiving L‐asparaginase intramuscularly merit prolonged observation periods beyond the usual one half to one hour.
Endometrial carcinoma after Hodgkin disease in childhood
Authors: Brown Gail , Li Frederick P. , Cohen Harvey , Cassady J. Robert , Goldstein Donald 
Published: February 2007

AbstractA 34‐year‐old patient developed metastatic endometrial carcinoma after Hodgkin disease in childhood. She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women. Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.
Malignant lymphoma with a high content of epithelioid histiocytes: Report of a T‐cell variant of so‐called lennert lymphoma and review of the literature
Authors: Han T. , Barcos M. , Yoon J. M. , Rakowski I. , Minowada J. 
Published: February 2007

AbstractThe present report describes the first case of well‐differentiated nodular lyraph‐ocytic lymphoma evolving into Lennert lymphoma of T‐cell origin. A 58‐year‐old white female developed malignant lymphoma, well‐differentiated, lympho‐cytic type, nodular, with focal bone marrow involvement (stage IV) in May 1975. She received 16 cycles of cyclophosphamide and prednisone combination chemotherapy which was completed in October 1976. A complete remission was achieved. In December 1976, she relapsed and was treated with cyclophosphamide, vincristine, bleomycin, and prednisone until May 1977. Lympha‐denopathy decreased until August 1978, but then increased again. Biopsy of an axillary lymph node was interpreted as Lennert lymphoma. She received methotrexate, cyclophosphanide, vincristine, adriamycin, and prednisone beginning in September 1978. When last seen in November 1979, she was in partial remission. Lymphoid cells obtained from lymph node which was involved with Lennert lymphoma consisted of 93% standard E‐rosettes and 83% gravity E‐rosettes. Cytoplasmic immunoglobulin on frozen sections was negative, but acid phosphatase (ACP) and alpha‐naphthyl acetate esterase reactions were strongly positive. These findings support a T‐cell proliferation in Lennert lymphoma. A review of the literature reveals only four cases of Lennert lymphoma of T‐cell origin.
Phase I evaluation of vindesine in children: A southwest oncology group pilot study
Authors: Komp Diane , Vats Tribhawan , Shepherd Dell A. , Vietti Teresa , Hoogstraten Barth , Haas Charles D. 
Published: February 2007

AbstractTwenty‐one children (19 with leukemia) were given 34 courses of vindesine on a weekly or twice‐weekly schedule in escalating doses. Thirty‐three courses were fully or partially evaluable for response and/or toxicity. Granulocyto‐penia was the dose‐limiting toxicity. Transient jaw, neck, or bone pain was common after each dose. Motor weakness, paresthesias, and constipation were neither frequent nor severe. In this Phase I study, vindesine had some antileu‐kemia activity in children previously treated with vincristine and other drugs. Phase II studies are warranted and a starting dose of 1.85 mg/m2 twice weekly appears tolerable.